OptiBiotix Health Plc announces the appointment of René Kamminga ("René") as Chief Executive Officer ("CEO") of OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health plc. OptiBiotix Ltd. contains OptiBiotix's SlimBiome®, SweetBiotix®, and microbiome modulating technology platforms. The intention is for René to join the OptiBiotix Health plc Board subject to completion of normal regulatory due diligence. The Company also announces the change of role of Dr Fred Narbel who will move from his position as Director on the OptiBiotix Board and Managing Director of the functional fibres division within OptiBiotix Ltd. to a more strategic role as Non-Executive Director of OptiBiotix Ltd. The Company also announces the change of role of Dr Fred Narbel who will move from his position as Director on the OptiBiotix Board and Managing Director of the functional fibres division within OptiBiotix Ltd. to a more strategic role as Non-Executive Director of OptiBiotix Ltd. René has more than 25 years' experience in the sale of speciality ingredients and products and joins from the position of Vice President of Business Development and Chief Commercial Officer of the Nutraceuticals division of KD Pharma Group ("KD Pharma").